



5th July 2023

New CFO Appointment

SomnoMed Limited (ASX “SOM”, or the Company), a leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (‘OSA’), announces the appointment of a new CFO, effective from 1 August 2023.

“We are pleased to announce that Mr Darren Collins has been appointed SomnoMed CFO from 1st August 2023,” said Mr Verdal-Austin, Managing Director and CEO of SomnoMed Limited. “Mr Collins comes with extensive global financial experience and a proven track record of driving transformational change and strategic growth. He has worked with both large (ASX listed) and smaller companies, including complex multinational organizations across diverse industries,” added Mr Verdal-Austin. “Mr Collins trained with KPMG and has built a track record of supporting growth and business transformation for global businesses. He has worked across Australia, Asia and the US, being based in Singapore and residing in the USA for ten years as a Group CFO,” continued Mr Verdal-Austin.

Mr Herve Fievet leaves the role after more than 4 years and the entire board and staff of SomnoMed thank him for the contribution he has made to the group over that time and wish him well with his future endeavours.

This release has been approved by the Board of SomnoMed Limited.

For further information please contact

Corporate

Mr. Neil Verdal-Austin
CEO SomnoMed
+61 406 931 477
Nverdalaustin@somnomed.com

Investors

Mr. Howard Marks
Automic Markets
+61 402 438 019
Howard.marks@automicgroup.com.au

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 790,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>